Tumor suppressor NDRG2 tips the balance of oncogenic TGF-b via EMT inhibition in colorectal cancer

Oncogenesis

Volumn 3, Issue 2, 2014, Pages

  Shen, L ^a   Qu, X ^b   Ma, Y ^a   Zheng, J ^c   Chu, D ^a   Liu, B ^a   Li, X ^a   Wang, M ^c   Xu, C ^c   Liu, N ^d   Yao, L ^a   Zhang, J ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

colorectal cancer; EMT; methylation; NDRG2; TGF

Indexed keywords

FIBRONECTIN; N MYC DOWNSTREAM REGULATED GENE 2; NERVE CELL ADHESION MOLECULE; PROTEIN; PROTEIN C MYB; PROTEIN MIZ 1; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; DNA BINDING; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GROWTH INHIBITION; HT 29 CELL LINE; HUMAN; HUMAN CELL; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 84906791490     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.48     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
3. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
4. Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl 1998; 30-31: 111-122.
5. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 2001; 12: 3328-3339.
6. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-5549.
7. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257-261.
8. Pietenpol JA, Holt JT, Stein RW, Moses HL. Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA 1990; 87: 3758-3762.
9. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
10. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
11. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000; 92: 1388-1402.
12. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
13. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-552.
14. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW et al. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995; 55: 5548-5550.
15. Schwarte-Waldhoff I, Klein S, Blass-Kampmann S, Hintelmann A, Eilert C, Dreschers S et al. DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene 1999; 18: 3152-3158.
16. Calonge MJ, Massague J. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 1999; 274: 33637-33643.
17. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 2003; 106: 342-347.
18. Choi SC, Kim KD, Kim JT, Kim JW, Yoon DY, Choe YK et al. Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett 2003; 553: 413-418.
19. Takahashi K, Yamada M, Ohata H, Honda K. Ndrg2 promotes neurite outgrowth of NGF-differentiated PC12 cells. Neurosci Lett 2005; 388: 157-162.
20. Zhang J, Li F, Liu X, Shen L, Liu J, Su J et al. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J Biol Chem 2006; 281: 39159-39168.
21. Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer 2007; 7: 192.
22. Chu D, Zhang Z, Li Y, Wu L, Zhang J, Wang W. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther 2011; 10: 47-56.
23. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
24. Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007; 56: 140-148.
25. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3: 1709-1723.
26. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132: 127-138.
27. Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG et al. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 2008; 29: 434-439.
28. Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002; 123: 1109-1119.
29. Douglas EJ, Fiegler H, Rowan A, Halford S, Bicknell DC, Bodmer W et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 2004; 64: 4817-4825.
30. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. Cancer Res 2007; 67: 10736-10743.
31. Wrana JL. Crossing Smads. Sci STKE 2000; 2000: re1.
32. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009; 19: 8-20.
33. Amati B. Integrating Myc and TGF-beta signalling in cell-cycle control. Nat Cell Biol 2001; 3: E112-E113.
34. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M et al. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 2011; 28: 137-155.
35. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3: 392-399.
36. Li CY, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995; 270: 4971-4974.
37. Pino MS, Kikuchi H, Zeng M, Herraiz MT, Sperduti I, Berger D et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010; 138: 1406-1417.
38. Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. EMBO J 2000; 19: 5178-5193.
39. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA 2000; 97: 9498-9503.
40. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
41. Ikeguchi M, Taniguchi T, Makino M, Kaibara N. Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol 2000; 35: 839-846.
42. Oh SS, Kim D, Kim DH, Chang HH, Sohn KC, Kim KH et al. NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-b production. Carcinogenesis 2012; 33: 1882-1888.
43. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 2008; 68: 4210-4220.
44. Kim YJ, Kang HB, Yim HS, Kim JH, Kim JW. NDRG2 positively regulates E-cadherin expression and prolongs overall survival in colon cancer patients. Oncol Rep 2013; 30: 1890-1898.
45. Smit MA, Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany, NY) 2010; 2: 735-741.
46. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S et al. p21CIP1 attenuates Ras-and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009; 106: 19035-19039.
47. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827-1831.